Clinical Trials on Waldenstrom's Macroglobulinemia Refractory

Total 2981 results

University Hospital, Lille
Celgene Corporation

Completed

Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia (RV-WM-0426)

Waldenstrom Macroglobulinemia

France
Jorge J. Castillo, MD
Bristol-Myers Squibb

Terminated

Dasatinib In Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia | DASATINIB

United States
The First Affiliated Hospital of Soochow University

Unknown

PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia

Treatment

China
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

Lymphoma

United States
LifeTime Pharmaceuticals

Unknown

Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States
NCIC Clinical Trials Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

Canada, United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States, Australia, United Kingdom, Canada, France
French Study Group on Chronic Lymphoid Leukemia
French Innovative Leukemia Organisation; Lymphoma Study Association; Département...

Completed

Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia

Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia | Lymphoplasmacytic Lymphoma

France
Fred Hutchinson Cancer Center
Mustang Bio

Recruiting

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic... and other conditions

United States
BeiGene

Recruiting

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia

United States, Puerto Rico
Shayna Sarosiek, MD
ADC Therapeutics S.A.

Recruiting

Loncastuximab Tesirine in WM

Waldenstrom Macroglobulinemia

United States
Fundación Española de Hematología y Hemoterapía

Recruiting

Spanish Registry of Patients With IgM Monoclonal Gammopathies (PRAME)

Waldenstrom Macroglobulinemia

Spain
University College, London
Janssen-Cilag Ltd.

Recruiting

Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia (RAINBOW)

Waldenstrom Macroglobulinemia

United Kingdom
Christian Buske
Hoffmann-La Roche; Johnson & Johnson; ClinAssess GmbH; University of Ulm; Zentrum...

Active, not recruiting

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

Waldenstrom Macroglobulinemia

Germany, Greece
Janssen Research & Development, LLC

Completed

A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

Waldenstrom Macroglobulinemia

China
University College, London
Merck Sharp & Dohme LLC

Completed

Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia (PembroWM)

Waldenstrom Macroglobulinemia

United Kingdom
Dana-Farber Cancer Institute
AbbVie

Completed

Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia

United States
Assistance Publique - Hôpitaux de Paris

Completed

Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia (WM2)

Waldenstrom Macroglobulinemia

France
University of Arkansas

Terminated

DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients

Waldenstrom Macroglobulinemia

United States
University of Arkansas
Celgene Corporation

Completed

Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia

Waldenstrom Macroglobulinemia

United States
Jonsson Comprehensive Cancer Center
Genentech, Inc.

Completed

Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Collecting Stem Cells in Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States, Puerto Rico, South Africa
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States, Canada, United Kingdom, Sweden
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Waldenstrom Macroglobulinemia | Lymphoplasmacytic Lymphoma

United States
The University of Hong Kong
Janssen, LP

Unknown

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Follicular Lymphoma | Chronic Hepatitis B | Chronic Lymphocytic Leukemia | Mantle-Cell Lymphoma | Lymphoma, Small Lymphocytic | Indolent B-cell Lymphomas | Waldenstrom's Macroglobulinaemia

Hong Kong
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Richter Syndrome and other conditions

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Terminated

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia

Lymphoma

United States
Taunton and Somerset Hospital

Completed

Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma

Lymphoma

Australia, United Kingdom
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States
Cancer Research UK
BioInvent International AB; Bloodwise

Completed

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

B-cell Lymphoma | Waldenström Macroglobulinemia | Chronic Lymphocytic Leukaemia

United Kingdom
Dana-Farber Cancer Institute
AbbVie; Pharmacyclics LLC.

Active, not recruiting

Ibrutinib + Venetoclax in Untreated WM

Waldenstrom Macroglobulinemia | MYD88 Gene Mutation

United States
Burzynski Research Institute

Withdrawn

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia

Waldenstrom Macroglobulinemia

United States
Seoul National University Hospital
Seoul National University Bundang Hospital

Unknown

Study of VTD in Waldenstrom's Macroglobulinemia (BOMB-THROW)

Waldenstrom Macroglobulinemia | Lymphoplasmacytic Lymphoma

Korea, Republic of
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Myeloid Metaplasia | Philadelphia Chromosome-negative CML | Advanced Polycythemia

United States
Joseph Tuscano
National Cancer Institute (NCI); Celgene

Active, not recruiting

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Hairy Cell Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
iOMEDICO AG

Recruiting

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms (RUBIN)

Chronic Lymphocytic Leukemia (CLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL) | Waldenström's Macroglobulinemia (WM)

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma

Lymphoplasmacytic Lymphoma

United States
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS (FIL_BIOWM)

Waldenstrom Macroglobulinemia

Italy
Centre Hospitalier Universitaire, Amiens
Centre Henri Becquerel; University Hospital, Caen; University Hospital, Lille; Centre... and other collaborators

Recruiting

Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia (SLPRaresHvisc)

Waldenstrom Macroglobulinemia | Hyperviscosity Syndrome

France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Waldenstrom Macroglobulinemia | Refractory Plasma Cell Myeloma | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia and other conditions

United States
Garden State Cancer Center at the Center for Molecular...
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia

Lymphoma | Leukemia

United States
Shayna Sarosiek, MD
AstraZeneca

Recruiting

ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

Waldenstrom Macroglobulinemia | Neuropathy;Peripheral | IgM MGUS

United States
Assistance Publique - Hôpitaux de Paris
INSERM UMR 1163

Not yet recruiting

Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies (GEN-HEMO-INF)

Multiple Myeloma | Waldenstrom Macroglobulinemia | Monoclonal Gammopathy of Undetermined Significance

France
Amgen

Terminated

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Multiple Myeloma | Waldenstrom Macroglobulinemia

United States
University Hospital, Strasbourg, France

Recruiting

B-cell Chronic Lymphoid Malignancies Markers (MALYZOMA-II)

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Hairy Cell Leukemia | Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia

France
German CLL Study Group

Completed

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Chronic Lymphocytic Leukemia

Canada, Germany
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

Recruiting

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | MALT Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Indolent Lymphoma | Refractory B-Cell Lymphoma

United States, Australia, China
University of Vermont
National Cancer Institute (NCI)

Completed

Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia

Lymphoma | Leukemia

United States

Clinical Trials on Waldenstrom's Macroglobulinemia Refractory

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations